Meeting
2018 ASCO Annual Meeting
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Authors
Michael Cecchini
Yale University, New Haven, CT
Michael Cecchini , Patricia LoRusso , Yu Shyr , S. Percy Ivy , Jeffrey Sklar , Kirsten Dooley , Jill Lacy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03008278
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4137)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4137
Abstract #
TPS4137
Poster Bd #
323a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Jian-Ming Xu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study.
First Author: Thorsten Oliver Goetze
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price